基本信息
浏览量:166
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Updated: 24 March 2022
Professor Dr. med. Markus OLLERT is Director of the Department of Infection and Immunity, Luxembourg Institute of Health (LIH), since September 2014, where he is leading basic and translational research with a focus on immune-related disorders including viral infection, autoimmunity, asthma, allergic rhinitis, anaphylaxis and neurodegeneration. He also holds a position as full professor in Clinical Allergology at Odense University Hospital of the University of Southern Denmark since 2015. He is scientific co-founder of Tolerogenics SàrL, Esch-sur-Alzette, Luxembourg.
Academic trajectory – Markus Ollert:
Before coming to Luxembourg, he was professor of Molecular Dermatology and Immunology at Technische Universität München (TUM), Munich, Germany, since 2000 and vice-chairman of the clinical Department of Dermatology and Allergy of TUM since 2006. Prof. Ollert pioneered a relevant line of translational research allowing to fill important missing gaps between laboratory research and molecular diagnostic application for patients with severe allergic diseases. He has served as chairperson of the Interest Group (IG) Allergy Diagnosis (IGAD) within the European Academy of Allergy and Clinical Immunology (EAACI), when he initiated the Task Force on Molecular Allergology that published the world’s first comprehensive Users’ Guide on Molecular Allergology with Prof. Ollert as senior author and editor in 2016. Since 2019, Prof. Ollert is member-at-large in the EAACI Executive Committee representing Western and Central Europe. Prof. Ollert is a clinician scientist with board certifications and clinical specializations in Dermatology and in Allergology. Prof. Ollert has published more than 250 articles in scientific journals or text books, of which 223 are listed in PubMed*. His scientific work has been cited more than 13.500-times by scientists around the world with an h-index of 65 in Google Scholar#. During the national effort in Luxembourg against the COVID-19 pandemic, Prof. Ollert has been heading the diagnostic work package (WP04) of the COVID-19 Task Force Research Luxembourg.
*PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Ollert+M&sort=date
#Google Scholar: https://scholar.google.com/citations?user=9uL0a-cAAAAJ&hl=de
Educational and Training activities - Markus Ollert:
Until 2022, Prof. Ollert has supervised or co-supervised (1990-2022) more than 50 MD, MD/PhD, PhD candidates or Post-doctoral fellows. Most of his previous fellows have contributed to society with careers in healthcare or science afterwards. Since 2017, Prof Ollert is coordinating the first PhD program in Luxembourg fully dedicated to immunology (NEXTIMMUNE) at the Luxembourg Institute of Health (LIH), with the Universities of Luxembourg (Uni-LU) and Southern Denmark (SDU) as PhD diploma-awarding institutions, bridging between wet lab immunology and computational big data research (funded with >2 Mio. EUR by the Luxembourg National Research Fund FNR) (https://www.lih.lu/page/nextimmune-dtu).
Entrepreneurial activities – Markus Ollert:
Prof. Ollert co-founded Protein-Ligand-Structural Design (PLS-Design GmbH) in Hamburg, Germany as a start-up of the Universities of Hamburg and of the TUM, Munich in 2004. PLS-Design became a leader in providing molecular diagnostic solutions for patients with severe allergic reactions caused by stinging insects such as honeybees and wasps. The technologies developed by PLS-Design were successfully licensed to diagnostic leaders in the field and are now marketed immunoassays for the diagnosis of insect venom allergy in the product portfolio of ThermoFisher/Phadia, Uppsala, Sweden. In 2016, Prof. Ollert co-founded Tolerogenics SàrL in Esch-sur-Alzette, Luxembourg. Tolerogenics is dedicated to provide solutions for the increasing burden of allergic diseases, which are affecting up to 40% of people in Westernized societies around the world. Tolerogenics wants to contribute to the vision of a world with less or less severe allergic diseases in the short- and mid-term range, and to a world without allergic diseases on a longer-term perspective. Allergen-specific immunotherapy and primary vaccination against allergy, which are the main business areas of Tolerogenics, are ideally tailored to reach these ambitious goals of sustainable allergy prevention and cure.
研究兴趣
论文共 478 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CLINICAL AND TRANSLATIONAL ALLERGYno. 2 (2024): n/a-n/a
Nature communicationsno. 1 (2024): 4259-4259
JOURNAL OF FOOD COMPOSITION AND ANALYSIS (2024): 105869
ALLERGY (2024)
B. Sousa-Pinto, Y. Palamarchuk, L. Leemann, S. Jankin,X. Basagana, J. Ballester,A. Bedbrook,W. Czarlewski,R. Almeida,T. Haahtela, H. Haveri, M. Prass,
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGYno. 1 (2024): 12-19
Stefania Arasi,Jean-Christoph Caubet, Ozlem Ceylan,Ibon Eguíluz-Gracia,Stefano Del Giacco,Aslı Gelincik,Marek Jutel,Rosan Meyer,Markus Ollert,Maria J Torres, Written the EAACI Formula Milk Industry Sponsorship Task Force
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunologyno. 5 (2024): e14142-e14142
PEDIATRIC ALLERGY AND IMMUNOLOGYno. 2 (2024): e14080-e14080
The Medical journal of Australiano. 8 (2024): 436-436
Olena Tsurkalenko, Dmitry Bulaev,Marc Paul O’Sullivan,Chantal Snoeck,Soumyabrata Ghosh,Alexey Kolodkin, Basile Rommes,Piotr Gawron, Carlos Vega Moreno,Clarissa P. C. Gomes,Anne Kaysen,Jochen Ohnmacht,
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn